- ISIN
- US09074F2074
- CUSIP
- 09074F207
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 5, 2014
Highlights
- Market Cap
- $14.64M
- Enterprise Value
- $1.91M
- EPS (TTM)
- -$2.25
- Gross Profit (TTM)
- -$229.38K
- EBITDA (TTM)
- -$19.89M
- Year Range
- $1.06 - $10.90
- ROA (TTM)
- -113.71%
- ROE (TTM)
- -127.61%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BIVI Performance Chart
BioVie Inc. (BIVI) is up 67.2% since the beginning of the year. At $2 per share, BIVI is trading 82.2% below its 52-week high of $11. Investors who bought $1,000 worth of BIVI shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
BioVie Inc. (BIVI) has returned 67.24% so far this year and -81.17% over the past 12 months. Over the last ten years, BIVI has returned -53.68% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
BioVie Inc.
- 1D
- 10.23%
- 1M
- 27.63%
- YTD
- 67.24%
- 6M
- 39.57%
- 1Y
- -81.17%
- 3Y*
- -85.07%
- 5Y*
- -74.18%
- 10Y*
- -53.68%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BIVI Monthly Returns History
Based on dividend-adjusted daily data since May 5, 2014, BIVI's average daily return is +0.48%, while the average monthly return is +3.22%. At this rate, an investment would double in approximately 1.8 years.
Historically, 40% of months were positive and 60% were negative. The best month was Jul 2018 with a return of +250.0%, while the worst month was Aug 2025 at -74.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, BIVI closed higher 34% of trading days. The best single day was Jun 11, 2014 with a return of +206.7%, while the worst single day was Oct 17, 2014 at -71.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.72% | 21.05% | 1.45% | 17.86% | -13.94% | 36.62% | 67.24% | ||||||
| 2025 | -17.50% | -19.39% | -26.32% | -16.56% | 27.19% | -11.06% | -35.08% | -74.69% | 25.00% | -7.89% | -14.29% | -22.67% | -94.20% |
| 2024 | -17.46% | 19.23% | -57.37% | -7.30% | -7.04% | -12.07% | -2.77% | -28.61% | -56.83% | 128.33% | 2.19% | -28.57% | -84.13% |
| 2023 | -34.75% | 51.68% | 5.07% | -1.11% | -26.91% | -26.20% | 9.51% | -34.11% | 9.65% | 27.86% | -58.72% | -30.00% | -83.78% |
| 2022 | -29.56% | -1.89% | 51.77% | -21.19% | -31.18% | -43.36% | 48.28% | 67.91% | -31.02% | 69.88% | 59.34% | 15.28% | 72.67% |
| 2021 | 93.48% | -4.21% | -39.75% | -9.46% | -21.47% | 23.27% | -16.58% | -43.56% | -16.17% | -8.52% | 5.23% | -30.12% | -74.02% |
Benchmark Metrics
BioVie Inc. has an annualized alpha of 196.08%, beta of 0.93, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 05, 2014.
- This stock participated in 89.70% of S&P 500 Index downside but only -117.32% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 196.08%
- Beta
- 0.93
- R²
- 0.01
- Upside Capture
- -117.32%
- Downside Capture
- 89.70%
Return for Risk
Risk / Return Rank
BIVI ranks 10 for risk / return — in the bottom 10% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioVie Inc. (BIVI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIVI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.87 | ||
| Sortino ratioReturn per unit of downside risk | -4.20 | ||
| Omega ratioGain probability vs. loss probability | 0.80 | 1.37 | -0.57 |
| Calmar ratioReturn relative to maximum drawdown | -0.90 | 2.78 | -3.69 |
| Martin ratioReturn relative to average drawdown | -1.01 | 12.44 | -13.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioVie Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioVie Inc. was 99.98%, occurring on Feb 5, 2026. The portfolio has not yet recovered.
The current BioVie Inc. drawdown is 99.97%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.98%Feb 2026 | 11y 9mo | — | 12y 1moMay 2014 - now |
Drawdown Indicators
| BIVI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -90.09% | -9.10% | -80.99% |
Max Drawdown (3Y)Largest decline over 3 years | -99.82% | -18.90% | -80.92% |
Max Drawdown (5Y)Largest decline over 5 years | -99.94% | -25.43% | -74.51% |
Max Drawdown (10Y)Largest decline over 10 years | -99.98% | -33.92% | -66.06% |
Current DrawdownCurrent decline from peak | -99.97% | -1.80% | -98.17% |
Average DrawdownAverage peak-to-trough decline | -79.67% | -10.71% | -68.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 80.67% | 2.03% | +78.64% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioVie Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioVie Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BIVI in comparison with other companies in the Biotechnology industry. Currently, BIVI has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BIVI
Add BioVie Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BIVI